

Forum diabetologicum 2013; 2

Regisler klíčových slov

| klíčové slovo | (číslo): strany | klíčové slovo | (číslo): strany |
|--|------------------------|---|------------------------|
| akútne srdcové zlyhávanie | (1): 23–26 | gliptíny | (2): 130–139 |
| akútny koronárny syndróm | (1): 23–26 | gravidita | (3): 176–180 |
| aliskirén | (1): 11–17 | | (3): 181–184 |
| antiagregačná liečba | (2): 68–73 | hypertriacylglycerolémie | (2): 140–145 |
| antidiabetiká | (1): 18–22 | hypolipidemika | (2): 68–73 |
| antihypertenzívne lieky | (1): 11–17 | chronická rana | (2): 98–101 |
| anti-VEGF | (3): 185–188 | indikčné obmedzenia | (2): 130–139 |
| AT1-blokátory | (2): 68–73 | inhibitory ACE | (2): 68–73 |
| aterogénna dyslipidémia | (2): 140–145 | intenzifikovaný inzulínový režim | (2): 122–124 |
| ateroskleróza | (2): 140–145 | inzulín lispro mix | (2): 122–124 |
| autonómna neuropatia | (2): 108–116 | jednoduchosť a finančná nenáročnosť | (2): 98–101 |
| bazálne analógy inzulínu | (2): 130–139 | kardiorenálny syndróm | (1): 31–35 |
| cievy | (2): 90–97 | kardiovaskulárne ochorenia | (1): 27–30 |
| cílová hodnota krvného tlaku | (2): 68–73 | kardiovaskulárna mortalita | (2): 102–107 |
| časná inzulínová terapia diabetu 2. typu | (3): 165–168 | kardiovaskulárne riziko | (3): 165–168 |
| časná kombinácia liečby | (3): 165–168 | komorová fibrilácia | (1): 36–40 |
| časná liečba diabetu | (3): 165–168 | kompliancia | (1): 11–17 |
| dermoepidermálne štepky | (2): 98–101 | komplikácie | (2): 108–116 |
| diabetes mellitus | (1): 18–22 | larvoterapia | (2): 74–83 |
| | (1): 23–26 | laserová liečba | (3): 176–180 |
| | (1): 27–30 | liečba prediabetu | (3): 165–168 |
| | (1): 31–35 | liečba pomocou živých bunkových línií | (2): 74–83 |
| | (1): 36–40 | liečba riadeným podtlakom | (2): 74–83 |
| | (2): 102–107 | mikroalbuminúria | (2): 117–121 |
| | (2): 108–116 | mikroalbuminurie | (2): 68–73 |
| | (2): 117–121 | multiorgánovomultivaskulárna choroba | (1): 36–40 |
| | (3): 190–192 | nefroprotektie | (2): 68–73 |
| diabetes mellitus 1. typu | (3): 185–188 | neovaskularizácie terča zrakového nervu | (3): 185–188 |
| diabetes mellitus 2. typu | (2): 122–124 | neovaskulárny glaukóm | (3): 190–192 |
| diabetes mellitus-výskyt | (3): 193–199 | pars plana vitrektómia | (3): 170–175 |
| diabetická kardiomyopatia | (1): 18–22 | periférna neuropatia | (2): 108–116 |
| diabetická nefropatia | (1): 31–35 | podiatrické centrum | (2): 102–107 |
| | (2): 117–121 | prediabetes | (3): 165–168 |
| | (S1): 1–6 | predsieňová fibrilácia | (1): 27–30 |
| diabetická noha | (2): 74–83 | premixované inzulínové analógy | (2): 122–124 |
| | (2): 90–97 | prevence diabetu | (3): 165–168 |
| | (2): 98–101 | primárny glaukóm s otvoreným uhlom | (3): 190–192 |
| diabetická retinopatia | (3): 170–175 | ranibizumab | (3): 185–188 |
| | (3): 176–180 | rehospitalizácie pre akútne ochorenia | (1): 23–26 |
| | (3): 181–184 | rizikové faktory | (2): 84–89 |
| | (3): 193–199 | skrining | (3): 176–180 |
| diabetické ulcerace | (2): 102–107 | srdcové zlyhávanie | (1): 18–22 |
| diabetický edém makuly | (3): 170–175 | syndróm diabetickej nohy | (2): 84–89 |
| | (3): 185–188 | tehotenstvo | (3): 181–184 |
| | (3): 193–199 | tlak vnútroočný | (3): 190–192 |
| diagnostika diabetickej nefropatie | (2): 117–121 | tolerancia | (1): 11–17 |
| dyslipoproteinémia | (2): 140–145 | transplantácia autológnych štepov | (2): 98–101 |
| endovaskulárne výkony | (2): 90–97 | trvanie účinku | (1): 11–17 |
| etiopatogenéza | (2): 84–89 | zobrazovacie metódy | (2): 90–97 |
| glaukóm | (3): 190–192 | | |

Forum diabetologicum 2013; 2

Index of key words

| key word | (číslo): strany | key word | (číslo): strany |
|-------------------------------|-----------------|--|-----------------|
| ACE inhibitors | (2): 68–73 | | (3): 176–180 |
| acute coronary syndrome | (1): 23–26 | | (3): 181–184 |
| acute heart failure | (1): 23–26 | | (3): 193–199 |
| aliskiren | (1): 11–17 | diagnosis of diabetic nephropathy | (2): 117–121 |
| angiotensin receptor blockers | (2): 68–73 | duration of action | (1): 11–17 |
| antidiabetics | (1): 18–22 | dyslipoproteinemia | (2): 140–145 |
| antihypertensive drugs | (1): 11–17 | early combination treatment | (3): 165–168 |
| antiplatelet therapy | (2): 68–73 | early insulin treatment in type 2 diabetes | (3): 165–168 |
| anti-VEGF | (3): 185–188 | early treatment of diabetes | (3): 165–168 |
| atherogenic dyslipidemia | (2): 140–145 | endovascular intervention | (2): 90–97 |
| atherosclerosis | (2): 140–145 | etiopathogenesis | (2): 84–89 |
| atrial fibrillation | (1): 27–30 | forgiveness | (1): 11–17 |
| autonomic neuropathy | (2): 108–116 | glaucoma | (3): 190–192 |
| basal insulin analogues | (2): 130–139 | gliptines | (2): 130–139 |
| blood vessels | (2): 90–97 | goal blood pressure | (2): 68–73 |
| cardiorenal syndrome | (1): 31–35 | heart failure | (1): 18–22 |
| cardiovascular disease | (1): 27–30 | hypertriglyceridemia | (2): 140–145 |
| cardiovascular mortality | (2): 102–107 | chronical wound | (2): 98–101 |
| cardiovascular risk | (3): 165–168 | imaging methods | (2): 90–97 |
| compliance | (1): 11–17 | indicating restrictions | (2): 130–139 |
| complications | (2): 108–116 | insulin lispro mix | (2): 122–124 |
| dermoepidermal skin grafts | (2): 98–101 | intensified insulin regimen | (2): 122–124 |
| diabetes mellitus | (1): 18–22 | intraocular pressure | (3): 190–192 |
| | (1): 23–26 | laser treatment | (3): 176–180 |
| | (1): 27–30 | lipid-lowering drugs | (2): 68–73 |
| | (1): 31–35 | maggot therapy | (2): 74–83 |
| | (1): 36–40 | microalbuminuria | (2): 68–73 |
| | (2): 102–107 | | (2): 117–121 |
| | (2): 108–116 | multiorganomultivasculare arterial disease | (1): 36–40 |
| | (2): 117–121 | neovascular glaucoma | (3): 190–192 |
| | (3): 190–192 | nephroprotection | (2): 68–73 |
| diabetes mellitus type 1 | (3): 185–188 | optic disc neovascularization | (3): 185–188 |
| diabetes mellitus type 2 | (2): 122–124 | pars plana vitrektómia | (3): 170–175 |
| diabetes mellitus-incidence | (3): 193–199 | peripheral neuropathy | (2): 108–116 |
| diabetes prevention | (3): 165–168 | prediabetes | (3): 165–168 |
| diabetic cardiomyopathy | (1): 18–22 | prediabetes treatment | (3): 165–168 |
| diabetic foot | (2): 74–83 | pregnancy | (3): 176–180 |
| | (2): 90–97 | | (3): 181–184 |
| | (2): 98–101 | premixed insulin analogues | (2): 122–124 |
| diabetic foot clinic | (2): 102–107 | primary open-angle glaucoma POAG | (3): 190–192 |
| diabetic foot syndrome | (2): 84–89 | ranibizumab | (3): 185–188 |
| diabetic foot ulcer | (2): 102–107 | rehospitalization for acute diseases | (1): 23–26 |
| diabetic macular edema | (3): 170–175 | risk factors | (2): 84–89 |
| | (3): 185–188 | screening | (3): 176–180 |
| | (3): 193–199 | simplicity and low cost | (2): 98–101 |
| diabetic nephropathy | (1): 31–35 | transplantation of autolog skin grafts | (2): 98–101 |
| | (2): 117–121 | treatment with controlled vacuum | (2): 74–83 |
| | (S1): 1–6 | treatment with live cell lines | (2): 74–83 |
| diabetic retinopathy | (3): 170–175 | ventricular fibrillation | (1): 36–40 |